The integration of AI in the stock market has opened up new opportunities for traders and investors to make well-informed decisions. Specifically, in the case of Organon & Co (OGN), Tickeron's Swing Trader for Beginners: Search for Trend Reversals (TA&FA) bot has been a top performer in their robot factory. Traders can access this bot through the Tickeron website and gain valuable insights into potential trading opportunities. By utilizing AI and technical analysis, the bot provides recommendations for buying and selling AI stock.
Organon & Co (OGN) has seen a rough start to the year, with the stock falling -25.36% over the last three months to $23.59 per share. However, the latest analysis from A.I.dvisor reveals that OGN could be ready for a rebound.
A.I.dvisor analyzed 57 stocks in the Pharmaceuticals: Major Industry for the 3-month period ending April 18, 2023, and found that 58.82% exhibited an Uptrend while 41.18% demonstrated a Downtrend. Despite OGN's recent decline, traders should take note of the Momentum Indicator turning positive on March 28, 2023. This shift indicates that the stock could be entering a new upward trend.
If the Momentum Indicator's past performance is any indication, traders may want to consider buying OGN stock or call options. Tickeron's A.I.dvisor analyzed 28 similar instances where the indicator turned positive, and in 21 of those cases, the stock moved higher in the following days. The odds of a move higher this time are at an impressive 75%.
Despite the recent dip, the positive Momentum Indicator coupled with the favorable odds for a move higher could make Organon & Co an attractive investment opportunity for traders. As always, it's important to conduct thorough research and analysis before making any investment decisions.
Our platform utilizes the power of AI to provide you with valuable insights and analysis, helping you make informed decisions when it comes to trading and investing. Don't miss out on this opportunity to take your stock market game to the next level. Register with us now and start making money! If you're interested in stocks and want to stay ahead of the game, consider registering with us, click here.
The 10-day RSI Indicator for OGN moved out of overbought territory on July 07, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where OGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
OGN broke above its upper Bollinger Band on June 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on June 10, 2026. You may want to consider a long position or call options on OGN as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OGN advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 209 cases where OGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.917) is normal, around the industry mean (19.926). P/E Ratio (14.484) is within average values for comparable stocks, (28.354). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.932). OGN has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.031). OGN's P/S Ratio (0.571) is slightly lower than the industry average of (4.255).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsMajor